Prolonged and enhanced secretion of glucagon-like peptide I (7-36 amide) after oral sucrose due to α-glucosidase inhibition (acarbose) in type 2 diabetic patients

Diabetic Medicine

Volumn 15, Issue 6, 1998, Pages 485-491

  Seifarth, C ^a   Bergmann, J ^a   Holst, J J ^b   Ritzel, R ^a   Schmiegel, W ^a   Nauck, M A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

glucosidase inhibition; Acarbose; GIP; GLP 1 (7 36 amide); NIDDM

Indexed keywords

ACARBOSE; GLUCAGON LIKE PEPTIDE 1; SUCROSE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PROTEIN SECRETION;

ACARBOSE; ADMINISTRATION, ORAL; AGED; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SUCROSE; TIME FACTORS; TRISACCHARIDES;

EID: 0031840283     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199806)15:6<485::AID-DIA610>3.0.CO;2-Y     Document Type: Article

References (44)

1. Varndell IM, Bishop AE, Sikri KL, Uttenthal LO, Bloom SR, Polak JM. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J Histochem Cytochem 1985; 33: 1080-1086.
2. Ørskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides CLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 19: 1467-1475.
3. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-174.
4. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide 1(7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619.
5. Cataland S, Crockett SE, Brown JC, Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab 1974; 39: 223-228.
6. Creutzfeldt W, Nauck MA. Gut hormones and diabetes mellitus. Diabetes/Metab Rev 1992; 8: 149-177.
7. Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917.
8. Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet 1987; II: 1300-1400.
9. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with Type 2 diabetes mellitus. J Clin Invest 1993b; 91: 301-307.
10. Kolligs F, Fehmann H-C, Göke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995; 44: 16-19.
11. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in the rat. J Clin Invest 1995; 95: 417-421.
12. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85.
13. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-1967.
14. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
15. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
16. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992; 15: 270-276.
17. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
18. Ørskov C, Holst JJ, Seier Poulsen S, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987; 30: 874-881.
19. Ørskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ. Complete sequences of glucagon-like peptide 1 from human and pig small intestine. J Biol Chem 1989; 264: 12826-12829.
20. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22: 283-291.
21. Sasaki H, Manaka H, Yamatani K, Tominaga M. GLP-1 secretion coupled with Na/glucose transporter from isolated perfused canine ileum. Digestion 1993; 54: 365-367.
22. Herrmann C, Vöge A, Göke B. Regulation of glucagon-like peptide release from the isolated perfused rat ileum by nutrients, peptides and neuromediators. Digestion 1993; 54: 367.
23. Fukase N, Takahashi H, Igarashi M. Differences in glucagon-like peptide 1 and GIP responses following sucrose ingestion. Diab Res Clin Prac 1992; 15: 187-195.
24. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. Scand J Gastroenterol 1995; 30: 892-896.
25. Qualmann C, Nauck M, Holst JJ, Ørskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995; 32: 13-16.
26. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K. F̈ucker K. Therapeutic potentials of acarbose as firstline drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-737.
27. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 1995; 18: 817-824.
28. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Influence of acarbose on GLP-1 release after a sucrose load in NIDDM patients. Diabetologia 1997; 40 (Suppl 1): A 131.
29. Müller FO, Hundt HKL, Luus HG, van Dyk M, Groenewald G, Hillebrand I. The disposition and pharmacokinetics of acarbose in man. In: Creutzfeldt W, ed. Acarbose for the Treatment of Diabetes Mellitus. Heidelberg: Springer, 1988: 17-24.
30. Lembcke B, Fölsch UR, Caspary WF, Ebert R, Creutzfeldt W. Influence of metronidazole on the breath hydrogen response and symptoms in acarbose-induced malabsorption of sucrose. Digestion 1983; 25: 186-193.
31. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sesstoft L. Diminished gastric inhibitory polypeptide (GIP) response to meal in newly diagnosed type 1-(insulin dependent) diabetics. J Clin Endocrinol Metabol 1983; 56: 1306-1312.
32. Ørskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 1987b; 47: 165-174.
33. Ørskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 1994; 43: 535-539.
34. Holst JJ. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982; 207: 381-388.
35. Caspary WF. Sucrose malabsorption in man after ingestion of α-glucosidase inhibitor. Lancet 1978; 2: 1231-1233.
36. Shima K, Suda T, Nishimoto K, Yoshimoto S. Relationship between molecular structures of sugars and their ability to stimulate the release of glucagon-like peptide 1 from canine ileal loops. Acta Endocrinol 1990; 123: 464-470.
37. Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, et al. Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995; 56: 493-501.
38. Fölsch UR, Lembcke B, Höpfner M, Deuticke U, Creutzfeldt W. The enteroinsular axis during treatment with α-glucosidase inhibitors. Front Horm Res 1987; 16: 197-205.
39. Ebert R, Creutzfeldt W. Decreased GIP secretion through impairment of absorption. Front Horm Res 1980; 7: 192-201.
40. Olsen WA, Korsmo H. The intestinal brush border membrane in diabetes. Studies of sucrase-isomaltase metabolism in rats with streptozotocin diabetes. J Clin Invest 1977; 60: 181-186.
41. Najjar S, Hampp LT, Rabkin R, Gray GM. Sucrase α-dextrinase in diabetic BioBreed rats: reversible alteration of subunit structure. Am J Physiol (Gastroenterology and Hepatology) 1991; 260: G 275-281.
42. Gutniak M, Linde B, Holst JJ, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994; 17: 1039-1044.
43. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1986; 77: 1525-1532.
44. Rizza R. The role of splanchnic glucose appearance in determining carbohydrate tolerance. Diabetic Med 1996; 13: 23-27.